Cooperative Agreement U2GGH001202

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $7,888,424 Cooperative Agreement under the Capacity Building Assistance (CBA) for High-Impact HIV Prevention program (CFDA 93.834) to HealthHIV, a national non-profit organization based in Washington, DC. The award, with a performance period from August 2024 to March 2029, supports two key components: 1) eLearning training for high-impact HIV prevention programs, and 2) organization/workforce development and management for...

This Project Grant award, worth $367,332.00 and funded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research), will support the "Precision HIV Prevention: Piloting a Youth Learning Health Community" project at Florida State University. The project aims to develop and test implementation strategies for optimizing the delivery of evidence-based HIV prevention interventions tailored for youth in North Florida, a region with high...

This $1,365,212 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program supports the development and testing of a peer-led dynamic choice HIV prevention intervention for women at elevated HIV risk in Uganda. The intervention aims to increase coverage of biomedical HIV prevention products such as oral pre-exposure prophylaxis (PrEP), the dapivirine vaginal ring (DVR), and long-acting cabotegravir (CAB-LA), as well as...

The federal Cooperative Agreement award for "PROVIDING CAPACITY BUILDING ASSISTANCE: TECHNICAL ASSISTANCE FOR HIGH-IMPACT PREVENTION PROGRAMS TO END THE US HIV EPIDEMIC" provides $4,989,475.00 in funding from the Centers for Disease Control and Prevention (CDC) under the Capacity Building Assistance (CBA) for High-Impact HIV Prevention program (CFDA 93.834). This five-year award, running from August 2024 to March 2029, supports The Regents of the University of California, San Francisco...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) totaling $381,487 aims to assess the implementation and early effects of long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP) among adolescent girls and young women in Zambia. The "Scaling Comprehensive Access to Long-Acting for Equitable and Effective Use of PrEP (SCALE-UP)" study will use...

This K23 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will fund a $364,832 implementation science study to deliver and evaluate an enhanced care intervention, HIV Prevention Plus Care (HP+ Care), for young men who have sex with men (YMSM) starting pre-exposure prophylaxis (PrEP) at two clinics. The HP+ Care intervention will include motivational interviewing and personalized health education to promote...

This $844,564 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will be used by Emory University to develop an implementation strategy for linking adolescent girls and young women in South Africa who experience intimate partner violence (IPV) to pre-exposure prophylaxis (PrEP) options, including long-acting PrEP modalities. The key objectives are to conduct formative research through qualitative...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $2,155,836 to the University of Miami to conduct a randomized controlled trial evaluating two social network strategies to increase the reach of HIV self-testing and PrEP information. The goal of the "TEST-TO-PREP" project is to assess the effectiveness, resource needs, and implementation factors of a...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), funded under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to determine the effect of integrating sexually transmitted infection (STI) testing with expanded pre-exposure prophylaxis (PrEP) options on PrEP use among pregnant women in Botswana. The $573,475 award, effective from September 2, 2024 to August 31, 2029, will support a randomized trial to evaluate...

This $2,127,639 federal Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund a multi-level integrated strategy to optimize PrEP adherence and accelerate implementation at scale for Black men who have sex with men (MSM). The strategy combines two evidence-based interventions: 1) The "Many Men, Many Voices" (3MV) group-level behavioral intervention to increase healthcare seeking behaviors,...